Enhanced Monoclonal Antibody Production in Hybridoma Cells by LPS and Anti‐mIgG

Martín-López, Alicia; Camacho, F. Garcı́a; Contreras-Gómez, Antonio; Grima, E. Molina

doi:10.1021/bp070191a

Cited by 5 publications

(2 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the mid-1970s, hybridoma technology was invented for production of mouse monoclonal antibodies with defined antigen specificities and neutralization activity for application in clinical therapies (Kelso et al, 2016;Hugwil, 2013;Tomita and Tsumoto, 2011;Martin-Lopez et al, 2007;Hencsey et al, 1996;Honda et al, 1990;Köhler and Milstein, 1975). Hybridomas can be generated by effective fusion of B cells and partner cells followed by screening of individual antibody producing cells.…”

Section: Hybridoma Technique B Cell Immortalization and Microneutralmentioning

confidence: 99%

Brief introduction of current technologies in isolation of broadly neutralizing HIV-1 antibodies

Sun

Yan

Tang³

et al. 2018

Virus Research

View full text Add to dashboard Cite

HIV/AIDS has become a worldwide pandemic. Before an effective HIV-1 vaccine eliciting broadly neutralizing monoclonal antibodies (bnmAbs) is fully developed, passive immunization for prevention and treatment of HIV-1 infection may alleviate the burden caused by the pandemic. Among HIV-1 infected individuals, about 20% of them generated cross-reactive neutralizing antibodies two to four years after infection, the details of which could provide knowledge for effective vaccine design. Recent progress in techniques for isolation of human broadly neutralizing antibodies has facilitated the study of passive immunization. The isolation and characterization of large panels of potent human broadly neutralizing antibodies has revealed new insights into the principles of antibody-mediated neutralization of HIV. In this paper, we review the current effective techniques in broadly neutralizing antibody isolation.

show abstract

Section: Hybridoma Technique B Cell Immortalization and Microneutralmentioning

confidence: 99%

Brief introduction of current technologies in isolation of broadly neutralizing HIV-1 antibodies

Sun

Yan

Tang³

et al. 2018

Virus Research

View full text Add to dashboard Cite

show abstract

“…A monoclonal antibody needs to be produced under well‐controlled conditions to assure a consistency of quality for critical uses such as found in clinical diagnosis. Often, the production must be carried out at bioreactor scales of hundreds of liters to meet demand 2. Use of multiple small scale cultures is not practical as it is tedious, expensive, and labor intensive.…”

Section: Introductionmentioning

confidence: 99%

Production and scale‐up of a monoclonal antibody against 17‐hydroxyprogesterone

Chua

Abdul-Rahman²,

Chisti

2012

Biotechnology Progress

View full text Add to dashboard Cite

The hybridoma 192 was used to produce a monoclonal antibody (MAb) against 17-hydroxyprogesterone (17-OHP), for possible use in screening for congenital adrenal hyperplasia (CAH). The factors influencing the MAb production were screened and optimized in a 2 L stirred bioreactor. The production was then scaled up to a 20 L bioreactor. All of the screened factors (aeration rate, stirring speed, dissolved oxygen concentration, pH, and temperature) were found to significantly affect production. Optimization using the response surface methodology identified the following optimal production conditions: 36.8°C, pH 7.4, stirring speed of 100 rpm, 30% dissolved oxygen concentration, and an aeration rate of 0.09 vvm. Under these conditions, the maximum viable cell density achieved was 1.34 ± 0.21 × 10(6) cells mL(-1) and the specific growth rate was 0.036 ± 0.004 h(-1) . The maximum MAb titer was 11.94 ± 4.81 μg mL(-1) with an average specific MAb production rate of 0.273 ± 0.135 pg cell(-1) h(-1) . A constant impeller tip speed criterion was used for the scale-up. The specific growth rate (0.040 h(-1) ) and the maximum viable cell density (1.89 × 10(6) cells mL(-1) ) at the larger scale were better than the values achieved at the small scale, but the MAb titer in the 20 L bioreactor was 18% lower than in the smaller bioreactor. A change in the culture environment from the static conditions of a T-flask to the stirred bioreactor culture did not affect the specificity of the MAb toward its antigen (17-OHP) and did not compromise the structural integrity of the MAb.

show abstract

Effects of hydroxyurea on monoclonal antibody production induced by anti-mIgG and LPS stimulation on murine B cell hybridomas

et al. 2010

View full text Add to dashboard Cite

Chemical treatment with hydroxyurea (HU) has been selected as a simple and low cost strategy to generate a cell population enriched for the G1 phase. After the chemical treatment with HU, cells were stimulated with anti-mIgG to test if the positive effects of anti-mIgG on CD40 expression and specific IgG2a production rate were improved upon a cell population with a higher percentage of cells in G1 phase at the beginning of the cell culture. In addition, other treatments assayed in this work were the cell stimulation with Lipopolysaccharide (LPS) both before and after the HU treatment. It has been observed that the use of HU under conditions able to maintain the cells in viable state (0.1 mM for 20 h), has a negative effect on CD40 expression and specific IgG2a production rate induced by anti-mIgG. The positive effect of LPS on cell stimulation induced by anti-mIgG is reduced on cells treated with HU.

show abstract

Enhanced Monoclonal Antibody Production in Hybridoma Cells by LPS and Anti‐mIgG

Cited by 5 publications

References 32 publications

Brief introduction of current technologies in isolation of broadly neutralizing HIV-1 antibodies

Brief introduction of current technologies in isolation of broadly neutralizing HIV-1 antibodies

Production and scale‐up of a monoclonal antibody against 17‐hydroxyprogesterone

Effects of hydroxyurea on monoclonal antibody production induced by anti-mIgG and LPS stimulation on murine B cell hybridomas

Contact Info

Product

Resources

About